Oxymetazoline hydrochloride combined with mometasone nasal spray for persistent nasal congestion (pilot study) 英文参考文献.docVIP

LETTERS TO THEEDITOR OxymetazolineHydrochloride CombinedWithMometasone NasalSprayforPersistentNasal Congestion(PilotStudy) toms,verydisturbingsomeofthetimeand/ordisturbingmost ofthetime).Allhadanasalcongestionscoreof1.5orgreater atthescreeningvisit(day7)andanaveragenasalcongestion score of 1.5 or greater at the baseline visit (day 1). The average nasal congestion score was calculated from during thelast3daysbeforebaselineandthemorningofthebaseline visit(i.e.,totalof7scores). 10 A20-dayrandomizeddoubleblind,placebocontrolled pilotstudyofpatients?18yearswithaminimum1-yearhistory ofmoderatetosevereNCthatfailedtorespondtoNGCSwere strati?edtomometasonenasalspray(MNS)100?geverynight or nightly and OXY 0.05% 2 sprays per nostril (s/n) 2 times daily versus MNS 100 ?g every night or nightly plus saline placebo(PL)2s/n2timesdaily(Fig.1). Patients completed diaries for NC and quality of life (QOL) and underwent intranasal examination for nasal and turbinate changes and rhinorrhea. Patients continued on NGCSafterstudytermination. TotheEditor: Nasal glucocorticosteroids (NGCS) are considered ?rst-linetherapyforallergicrhinitisandareeffectivetherapy for nonallergic rhinitis, especially vasomotor rhinitis and nonallergic rhinitis with eosinophilia syndrome.1–4 congestion can persist despite maximum treatment with NGCS. Although oralandtopical antihistamines areeffec- 5,6 tive in relieving this symptom, neither oral nor topical antihistamines are as effective in relieving this symptom compared with NGCS. Oxymetazoline (OXY) is a de- congestant and the addition of oxymetazoline to a NGCS should add aconsiderable decongestant bene?t. However, its use isrecommended only for 3–14 days because ofthe risk ofrhinitis medicamentosa (RM), increased nasal con- Nasal 7,8 RESULTS Twenty-three patients met inclusion criteria. The MNS plusOXYcohortversusMNSplusPLachievedanaveragedNC score of 1.68 versus 2.06 (NS), respectively (Fig. 2). The treatmentgroupreported22%improvementinaveragedailyNC